Evotec SE (EVO)
- Previous Close
5.10 - Open
5.04 - Bid 3.62 x 200
- Ask 6.43 x 200
- Day's Range
5.02 - 5.11 - 52 Week Range
4.87 - 13.49 - Volume
704,966 - Avg. Volume
86,722 - Market Cap (intraday)
1.797B - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-0.28 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.80
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
www.evotec.com5,061
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: EVO
Performance Overview: EVO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVO
Valuation Measures
Market Cap
1.74B
Enterprise Value
1.70B
Trailing P/E
--
Forward P/E
45.45
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.05
Price/Book (mrq)
1.48
Enterprise Value/Revenue
2.08
Enterprise Value/EBITDA
-26.94
Financial Highlights
Profitability and Income Statement
Profit Margin
-10.74%
Return on Assets (ttm)
0.03%
Return on Equity (ttm)
-7.27%
Revenue (ttm)
781.43M
Net Income Avi to Common (ttm)
-83.91M
Diluted EPS (ttm)
-0.28
Balance Sheet and Cash Flow
Total Cash (mrq)
604.11M
Total Debt/Equity (mrq)
55.91%
Levered Free Cash Flow (ttm)
-69.81M
Research Analysis: EVO
Company Insights: EVO
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: EVO
Analyst Report: Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 65% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 35% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
RatingPrice TargetAnalyst Report: Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 75% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 25% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2022, the company has almost 5,000 employees and 17 production sites mainly in Europe and the United States.
RatingPrice TargetAnalyst Report: Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 75% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 25% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2022, the company has almost 5,000 employees and 17 production sites mainly in Europe and the United States.
RatingPrice Target